- Advertisement -
More
    - Advertisement -
    - Advertisement -
    HomeNewsCDC reports Mpox cases are far outpacing last year's numbers

    CDC reports Mpox cases are far outpacing last year’s numbers

    Health officials report that over 570 cases of mpox have been detected in the U.S. so far in 2024, marking a significant increase compared to this time last year.

    While this year’s infection rate remains lower than the peak observed during the mpox outbreak in early August 2022, when the country witnessed an average of about 470 new cases per week, the latest data underscore that mpox continues to circulate. Health authorities stress the importance of vaccination, particularly for individuals at risk of infection.

    Los Angeles County of Public health reports a total of 2,591 of mpox cases (includes Long Beach and Pasadena) since it began tracking infections. Two people have died in LA County.

    The primary mpox vaccine used in the U.S., known as JYNNEOS, is administered in two doses, spaced a month apart. Full vaccination is achieved two weeks after the second dose, with no current recommendations for booster shots. Eligibility and vaccine distribution locations can be found on the Centers for Disease Control and Prevention (CDC) website, as well as through various local health departments, including those of New York City and San Francisco.

    Vaccination is not universally recommended; specific groups, such as gay and bisexual men with recent sexually transmitted infection (STI) diagnoses, are identified as at-risk populations eligible for vaccination.

    Dr. Jenni McQuiston, deputy director of the CDC’s High-Consequence Pathogens and Pathology division, emphasized that most reported cases are among individuals who are either unvaccinated or under-vaccinated, reports Live Science.

    Mpox, formerly known as monkeypox, is caused by a virus related to the variola virus, which causes smallpox. There are two main types of mpox viruses: clade I and clade II. Clade I is associated with more severe and fatal disease outcomes. While clade I has not been detected in the U.S. to date, there remains a risk of introduction through travelers from regions like the Democratic Republic of the Congo.

    Symptoms of mpox can include fever, muscle aches, fatigue, and swollen lymph nodes, with characteristic pox rashes that progress from discolored patches to raised bumps, blisters, and scabbing. Individuals with weakened immune systems, infants, those with a history of eczema, and pregnant individuals face a higher risk of severe disease.

    Since the onset of the mpox outbreak in May 2022, the U.S. has reported over 30,000 cases, with the majority occurring in 2022. Although infection rates slowed by early 2023, recent data indicate a resurgence, with 576 cases reported between January 1 and March 23, 2024, according to provisional CDC figures.

    Notable concentrations of cases in 2024 include over 110 in New York City, 64 in California, and 50 in Florida.

    While mpox can affect anyone, certain groups, including gender-diverse and transgender individuals, as well as men who have sex with men, are disproportionately impacted. Efforts to increase vaccination rates among these populations are ongoing, as data suggest that many at-risk individuals have not received the recommended doses.

    Dr. Brandy Darby, director of the Division of Surveillance and Investigation at the Virginia Department of Health, emphasized the continued risk posed by mpox and stressed the importance of public awareness and vaccination efforts. Virginia has already noted a significant increase in mpox cases in 2024 compared to the previous year.

    5 2 votes
    Article Rating

    10 COMMENTS

    Subscribe
    Notify of
    guest
    10 Comments: We Want to Hear from You!
    newest
    oldest most voted
    Inline Feedbacks
    View all comments
    Cy Husain
    Cy Husain
    Offline
    15 days ago

    Great News BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine (BNT166) Development and Support. Recently multivalent mRNA monkeypox virus vaccine (BNT166) has shown it protects mice and macaques from orthopoxvirus disease. Before this it was shown mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. A month ago mRNA vaccine generated greater neutralizing and cellular spread-inhibiting activity against Mpox and VACV, as well as enhanced Fc-effector Th1-biased humoral immunity to the four Mpox antigens and the four VACV homologs, compared to the current Mpox vaccine, MVA.An FDA approved (EUA) mRNA Mpox vaccine may be on the way… Read more »

    Biontectmpox
    West
    West
    Offline
    20 days ago

    Just a reminder that as of today, there are no randomized controlled trials to provide direct evidence of the efficacy and safety of the JYNNEOS vaccines against mpox in humans. JYNNEOS as currently administered was approved under Emergency Use Authorization, citing animal studies only. Additionally, while there is some data correlating vaccine uptake with lower rates of infection among eligible populations, there is clear evidence that infection can still occur after vaccination. In a recent observational study of 276 individuals at a single hospital setting, who were vaccinated after exposure, 12 participants (4%) had a confirmed MPXV breakthrough infection; of those,… Read more »

    Last edited 20 days ago by West
    Cy Husain
    Cy Husain
    Offline
    Reply to  West
    18 days ago

    Very dangerous misinformation❗ Yes there is some In Vitro (in test tube) antiviral activity with sarracenia purpurea extracts but, that does NOT appear to be the case In Vivo (in body). In the case of the antiviral activity (halting replication) of this plant extract seen in In Vitro experiments, they are in concentrations NOT possible to attain in a living body! Going as far back to 1862 sarracenia purpurea was found to be ineffective to cure or prevent ANY pox disease. There are NO FDA-approved treatments for mpox & they are now cracking down on Illegally Sold Monkeypox (Mpox) Products.… Read more »

    Cy Husain
    Cy Husain
    Offline
    Reply to  West
    18 days ago

    The study you cited with only a 4% MPXV “infection” and NOT full blown mpox disease is an excellent result well able to establish herd immunity. Note “no severe adverse events or safety concerns were identified” clearly supporting the JYNNEOS vaccine’s safety. Note that JYNNEOS vaccine is licensed as a series of TWO doses administered 28 days (4 weeks) apart. The subjects were exposed to heavy viral loads, and the break through infections occurred after their FIRST dose.

    Cy Husain
    Cy Husain
    Offline
    Reply to  West
    18 days ago

    You might want to see Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States, yes the FDA approved its Emergency Use Authorization but, there was far more than just animal studies proving that JYNNEOS will do far more good than any possible harm. Note that sarracenia purpurea extracts FAILED to meet these standards.

    West
    West
    Offline
    Reply to  Cy Husain
    18 days ago

    Yes the Purple Pitcher Plant research demonstrating interruption of viral transcription on mpox is in vitro, but the important factor is that the plant has centuries of traditional use in humans and its safety profile well established. While there are numerous correlation studies of JYNNEOS, the points still stand that JYNNEOS has no randomized controlled clinical studies demonstrating safety and efficacy in humans, and that break through infections can still occur. Nothing I have said is misinformation.

    Cy Husain
    Cy Husain
    Offline
    Reply to  West
    15 days ago

    Systematic Review on the Efficacy, Effectiveness, Safety, and Immunogenicity of Monkeypox Vaccine Vaccine efficacy is a measure of how well the mpox vaccine prevents the incidence of the disease, typically under controlled and ideal conditions. It is determined through RCTs by comparing the incidence of the disease in a vaccinated group with that in a placebo-controlled group.”

    Cy Husain
    Cy Husain
    Offline
    20 days ago
    C'mon Sense
    C'mon Sense
    Offline
    21 days ago

    Must be an election year! lolz

    Cy Husain
    Cy Husain
    Offline
    Reply to  C'mon Sense
    20 days ago

    And consistently everywhere on Earth where disease containment measures were ignored there have been dire consequences❗

    TrumpCovid-2
    RELATED ARTICLES
    - Advertisment -

    Recent Comments On WEHO TIMES

    Latest Articles

    10
    0
    Would love your thoughts, please comment.x